Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 4

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 4
---
 time we elect to sell shares tothe Selling Shareholder and, further, to the extent that we sell Depositary Shares under the Equity Financing, substantial amounts of Depositary Shares could be issued and resold, which would cause dilution and may impact our stock price.

This prospectus provides you
with a general description of such securities and the general manner in which the Selling Shareholder may offer or sell the securities.
More specific terms of any securities that the Selling Shareholder may offer or sell may be provided in a prospectus supplement that describes,
among other things, the specific amounts and prices of the securities being offered and the terms of the offering. The prospectus supplement
may also add, update or change information contained in this prospectus.

The Selling Shareholder may
offer, sell or distribute all or a portion of the Depositary Shares acquired under the Purchase Agreement and hereby registered publicly
or through private transactions at prevailing market prices or at negotiated prices. We will bear all costs, expenses and fees in connection
with the registration of the Depositary Shares, including with regard to compliance with state securities or “blue sky” laws.
The timing and amount of any sales are within the sole discretion of the Selling Shareholder. The Selling Shareholder is an underwriter
under the Securities Act of 1933, as amended, with respect to the resale of shares held by it. Although the Selling Shareholder is obligated
to purchase Depositary Shares under the terms and subject to the conditions and limitations of the Purchase Agreement to the extent we
choose to sell such Depositary Shares to it (subject to certain conditions), there can be no assurances that we will choose to sell any
Depositary Shares to the Selling Shareholder, or that the Selling Shareholder will sell any or all of the Depositary Shares, if any, purchased
under the Purchase Agreement pursuant to this prospectus. The Selling Shareholder will bear all commissions and discounts, if any, attributable
to its sale of Depositary Shares. See “Plan of Distribution.”

Our Depositary Shares are
listed on the NASDAQ Capital Market under the symbol “BDRX.” The last reported closing price of our Depositary Shares on the
NASDAQ Capital Market on April 28, 2025 was $1.52.

Investing in our securities involves risks. See “Risk Factors” beginning on page 10 of this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.

Neither the Securities and Exchange Commission nor any state securities commission has